Literature DB >> 15113924

Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses.

Michael Garbutt1, Ryan Liebscher, Victoria Wahl-Jensen, Steven Jones, Peggy Möller, Ralf Wagner, Viktor Volchkov, Hans-Dieter Klenk, Heinz Feldmann, Ute Ströher.   

Abstract

Replication-competent recombinant vesicular stomatitis viruses (rVSVs) expressing the type I transmembrane glycoproteins and selected soluble glycoproteins of several viral hemorrhagic fever agents (Marburg virus, Ebola virus, and Lassa virus) were generated and characterized. All recombinant viruses exhibited rhabdovirus morphology and replicated cytolytically in tissue culture. Unlike the rVSVs with an additional transcription unit expressing the soluble glycoproteins, the viruses carrying the foreign transmembrane glycoproteins in replacement of the VSV glycoprotein were slightly attenuated in growth. Biosynthesis and processing of the foreign glycoproteins were authentic, and the cell tropism was defined by the transmembrane glycoprotein. None of the rVSVs displayed pathogenic potential in animals. The rVSV expressing the Zaire Ebola virus transmembrane glycoprotein mediated protection in mice against a lethal Zaire Ebola virus challenge. Our data suggest that the recombinant VSV can be used to study the role of the viral glycoproteins in virus replication, immune response, and pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15113924      PMCID: PMC400370          DOI: 10.1128/jvi.78.10.5458-5465.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Identification of Lassa virus glycoprotein signal peptide as a trans-acting maturation factor.

Authors:  Robert Eichler; Oliver Lenz; Thomas Strecker; Markus Eickmann; Hans-Dieter Klenk; Wolfgang Garten
Journal:  EMBO Rep       Date:  2003-10-10       Impact factor: 8.807

2.  Characterization of membrane components of the erythrocyte involved in vesicular stomatitis virus attachment and fusion at acidic pH.

Authors:  P Mastromarino; C Conti; P Goldoni; B Hauttecoeur; N Orsi
Journal:  J Gen Virol       Date:  1987-09       Impact factor: 3.891

3.  Cell-mediated immunity to vesicular stomatitis virus infections in mice.

Authors:  R M Zinkernagel; B Adler; J J Holland
Journal:  Exp Cell Biol       Date:  1978

4.  Fewer protective cytotoxic T-cell epitopes than T-helper-cell epitopes on vesicular stomatitis virus.

Authors:  T M Kündig; I Castelmur; M F Bachmann; D Abraham; D Binder; H Hengartner; R M Zinkernagel
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

5.  Ecologic studies of vesicular stomatitis virus. I. Prevalence of infection among animals and humans living in an area of endemic VSV activity.

Authors:  R B Tesh; P H Peralta; K M Johnson
Journal:  Am J Epidemiol       Date:  1969-09       Impact factor: 4.897

6.  Contrasting effects of matrix protein on apoptosis in HeLa and BHK cells infected with vesicular stomatitis virus are due to inhibition of host gene expression.

Authors:  Sarah A Kopecky; Douglas S Lyles
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

7.  Mutational analysis of the putative fusion domain of Ebola virus glycoprotein.

Authors:  H Ito; S Watanabe; A Sanchez; M A Whitt; Y Kawaoka
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 8.  Ebola virus: from discovery to vaccine.

Authors:  Heinz Feldmann; Steven Jones; Hans-Dieter Klenk; Hans-Joachim Schnittler
Journal:  Nat Rev Immunol       Date:  2003-08       Impact factor: 53.106

9.  Filovirus contamination of cell cultures.

Authors:  C J Peters; P B Jahrling; T G Ksiazek; E D Johnson; H W Lupton
Journal:  Dev Biol Stand       Date:  1992

10.  Vesicular stomatitis virus Indiana glycoprotein as a T-cell-dependent and -independent antigen.

Authors:  G Freer; C Burkhart; I Ciernik; M F Bachmann; H Hengartner; R M Zinkernagel
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

View more
  179 in total

Review 1.  Filovirus vaccines.

Authors:  Steven B Bradfute; John M Dye; Sina Bavari
Journal:  Hum Vaccin       Date:  2011-06-01

2.  Clinical aspects of Marburg hemorrhagic fever.

Authors:  Masfique Mehedi; Allison Groseth; Heinz Feldmann; Hideki Ebihara
Journal:  Future Virol       Date:  2011-09       Impact factor: 1.831

3.  Construction of a Sonchus Yellow Net Virus minireplicon: a step toward reverse genetic analysis of plant negative-strand RNA viruses.

Authors:  Uma Ganesan; Jennifer N Bragg; Min Deng; Sharon Marr; Mi Yeon Lee; Shasha Qian; Manling Shi; Justin Kappel; Cole Peters; Yeon Lee; Michael M Goodin; Ralf G Dietzgen; Zhenghe Li; Andrew O Jackson
Journal:  J Virol       Date:  2013-07-24       Impact factor: 5.103

4.  Discovery of Adamantane Carboxamides as Ebola Virus Cell Entry and Glycoprotein Inhibitors.

Authors:  Michael B Plewe; Nadezda V Sokolova; Vidyasagar Reddy Gantla; Eric R Brown; Shibani Naik; Alexandra Fetsko; Donald D Lorimer; David M Dranow; Hayden Smutney; Jameson Bullen; Rana Sidhu; Arshil Master; Junru Wang; E Adam Kallel; Lihong Zhang; Birte Kalveram; Alexander N Freiberg; Greg Henkel; Ken McCormack
Journal:  ACS Med Chem Lett       Date:  2020-05-01       Impact factor: 4.345

5.  Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial.

Authors:  May S ElSherif; Catherine Brown; Donna MacKinnon-Cameron; Li Li; Trina Racine; Judie Alimonti; Thomas L Rudge; Carol Sabourin; Peter Silvera; Jay W Hooper; Steven A Kwilas; Nicole Kilgore; Christopher Badorrek; W Jay Ramsey; D Gray Heppner; Tracy Kemp; Thomas P Monath; Teresa Nowak; Shelly A McNeil; Joanne M Langley; Scott A Halperin
Journal:  CMAJ       Date:  2017-06-19       Impact factor: 8.262

6.  Mechanism of human antibody-mediated neutralization of Marburg virus.

Authors:  Andrew I Flyak; Philipp A Ilinykh; Charles D Murin; Tania Garron; Xiaoli Shen; Marnie L Fusco; Takao Hashiguchi; Zachary A Bornholdt; James C Slaughter; Gopal Sapparapu; Curtis Klages; Thomas G Ksiazek; Andrew B Ward; Erica Ollmann Saphire; Alexander Bukreyev; James E Crowe
Journal:  Cell       Date:  2015-02-26       Impact factor: 41.582

7.  Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.

Authors:  Guido Wollmann; Eugene Drokhlyansky; John N Davis; Connie Cepko; Anthony N van den Pol
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

8.  Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections.

Authors:  Andrea Marzi; Heinz Feldmann; Thomas W Geisbert; Darryl Falzarano
Journal:  J Bioterror Biodef       Date:  2011-09-25

9.  A Recombinant Vesicular Stomatitis Virus Ebola Vaccine.

Authors:  Jason A Regules; John H Beigel; Kristopher M Paolino; Jocelyn Voell; Amy R Castellano; Zonghui Hu; Paula Muñoz; James E Moon; Richard C Ruck; Jason W Bennett; Patrick S Twomey; Ramiro L Gutiérrez; Shon A Remich; Holly R Hack; Meagan L Wisniewski; Matthew D Josleyn; Steven A Kwilas; Nicole Van Deusen; Olivier Tshiani Mbaya; Yan Zhou; Daphne A Stanley; Wang Jing; Kirsten S Smith; Meng Shi; Julie E Ledgerwood; Barney S Graham; Nancy J Sullivan; Linda L Jagodzinski; Sheila A Peel; Judie B Alimonti; Jay W Hooper; Peter M Silvera; Brian K Martin; Thomas P Monath; W Jay Ramsey; Charles J Link; H Clifford Lane; Nelson L Michael; Richard T Davey; Stephen J Thomas
Journal:  N Engl J Med       Date:  2015-04-01       Impact factor: 91.245

Review 10.  The search for animal models for Lassa fever vaccine development.

Authors:  Igor S Lukashevich
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.